新聞報導於大約1年前
Eli Lilly's drug tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight loss, has the potential to target the non-alcoholic steatohepatitis (NASH) market, a field with a significant unmet need as the first NASH medicine in the U.S. was just approved this year. Tirzepatide showed promising results in phase 2 studies, sparking hope for future success in treating NASH. While the NASH market is competitive, Eli Lilly's overall pipeline and revenue growth suggest a positive outlook for the company, with analysts predicting substantial earnings growth annually and strong potential for investment.
小見聞來源: YAHOO